Agenus Inc
AGEN2.940USD
+0.170+6.14%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
96.47MMarket Cap
LossP/E TTM
More Details of Agenus Inc Company
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc Info
Ticker SymbolAGEN
Company nameAgenus Inc
IPO dateFeb 04, 2000
CEOArmen (Garo H)
Number of employees316
Security typeOrdinary Share
Fiscal year-endFeb 04
Address3 Forbes Rd
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421-7305
Phone17816744400
Websitehttps://agenusbio.com/
Ticker SymbolAGEN
IPO dateFeb 04, 2000
CEOArmen (Garo H)
Company Executives of Agenus Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
29.77K
+7691.00%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+15782.00%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
29.77K
+7691.00%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+15782.00%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Non-cash royalty revenue
29.15M
96.40%
Clinical product revenue
1.09M
3.60%
Other services
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
30.23M
100.00%
Rest of World
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Non-cash royalty revenue
29.15M
96.40%
Clinical product revenue
1.09M
3.60%
Other services
0.00
0.00%
Shareholding Stats
Updated: 4 hours ago
Updated: 4 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.83%
Zydus Lifesciences Ltd
5.90%
Invus Public Equities Advisors, LLC
2.94%
Morgan Stanley & Co. LLC
1.37%
BlackRock Institutional Trust Company, N.A.
1.30%
Other
80.66%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.83%
Zydus Lifesciences Ltd
5.90%
Invus Public Equities Advisors, LLC
2.94%
Morgan Stanley & Co. LLC
1.37%
BlackRock Institutional Trust Company, N.A.
1.30%
Other
80.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.06%
Corporation
5.90%
Investment Advisor/Hedge Fund
4.37%
Hedge Fund
3.03%
Research Firm
2.80%
Individual Investor
1.68%
Pension Fund
0.34%
Other
65.82%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
304
9.95M
37.38%
--
2025Q3
332
9.95M
41.39%
+217.92K
2025Q2
334
9.73M
47.54%
+407.61K
2025Q1
334
9.33M
45.75%
-2.82M
2024Q4
341
8.45M
52.98%
-249.79K
2024Q3
351
8.70M
54.68%
-447.45K
2024Q2
347
9.21M
64.12%
-1.91M
2024Q1
356
10.69M
65.28%
-2.98M
2023Q4
374
11.90M
61.88%
+645.94K
2023Q3
382
11.27M
62.51%
+267.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
2.57M
7.56%
+36.98K
+1.46%
Sep 30, 2025
Invus Public Equities Advisors, LLC
1.06M
3.13%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
493.52K
1.45%
-226.23K
-31.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
468.79K
1.38%
-20.89K
-4.27%
Sep 30, 2025
Armen (Garo H.)
367.59K
1.08%
+9.26K
+2.58%
Dec 26, 2025
BofA Global Research (US)
369.31K
1.09%
-51.36K
-12.21%
Sep 30, 2025
Millennium Management LLC
348.75K
1.03%
-155.75K
-30.87%
Sep 30, 2025
Geode Capital Management, L.L.C.
346.99K
1.02%
+29.58K
+9.32%
Sep 30, 2025
Walleye Capital LLC
310.79K
0.91%
+112.50K
+56.74%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
